explore -WSS

explore

author：Wikipedia 2025-09-27 12:23:17 - browse：79514

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA official pushes for dedicated emerging pathogens team

explore

WSS

How artificial intelligence is being used to detect, treat cancer

Mass General Brigham physicians react to latest merger step

Oral obesity drug from Viking Therapeutics hits key early target

Court strikes down limits on filming of police in Arizona

Pancreatic cancer is often deadly, but new discoveries are raising hope

Bird flu in dairy cattle: New measures to control spread to humans

hotspot

explore

explore

Alkermes shareholders re

Trial using CRISPR to edit HIV out of cells disappoints

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Bird flu reported in person exposed to presumably infected cattle

In age of alternative facts, a scholarly course on calling out crap

Insurer loopholes limit power of law against surprise medical bills

DIEP, the 'gold standard' of breast reconstruction, is under threat

Scientists uncover potential path to treating deadly childhood tumor

Drug repurposing or repositioning? The language matters

Mass General Brigham physicians react to latest merger step

focus

Organ transplantation is at a crossroads. Major reform is needed

People with mental disorders often marry others with same

Gut bacteria may contribute to kidney autoimmunity, study finds

Study: Black kids more likely to die after surgery than white kids

UnitedHealth, in a surprise, takes aim at Steward’s physician group

New rules on organ donation and transplantation 'will bring chaos'

hotspot

explore

focus

hotspot